Advertisement
U.S. markets open in 34 minutes
  • S&P Futures

    5,304.75
    -3.50 (-0.07%)
     
  • Dow Futures

    40,156.00
    +12.00 (+0.03%)
     
  • Nasdaq Futures

    18,481.25
    -22.50 (-0.12%)
     
  • Russell 2000 Futures

    2,139.00
    +0.60 (+0.03%)
     
  • Crude Oil

    82.71
    +1.36 (+1.67%)
     
  • Gold

    2,227.10
    +14.40 (+0.65%)
     
  • Silver

    24.65
    -0.10 (-0.41%)
     
  • EUR/USD

    1.0801
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.2220
    +0.0260 (+0.62%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2634
    -0.0004 (-0.03%)
     
  • USD/JPY

    151.2000
    -0.0460 (-0.03%)
     
  • Bitcoin USD

    70,463.80
    +365.81 (+0.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,953.93
    +21.95 (+0.28%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 13, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (RDY). Investors, who purchased or otherwise acquired shares between June 17, 2015 and August 10, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the October 24, 2017 lead plaintiff motion deadline.

If you purchased Dr. Reddy's shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that it lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, the Company disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary, Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy's lowered in value materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

Advertisement